New oncology trial designs and equipoise: Commentary on Heynemann et al.
Clinical Trials · 2026
DOI: 10.1177/17407745261471455 ↗Kurz gefasst
Kommentar in der Zeitschrift Clinical Trials, 2026. Verfasst von Jonathan Kimmelman. Beteiligte Einrichtung: Department of Equity, Ethics and Policy, School of Population and Global Health, McGill University, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Research Design, Clinical Trials as Topic, Therapeutic Equipoise, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This essay responds to Heymemann et al.’s analysis of the applicability of clinical equipoise to emerging trial methods in cancer. Briefly, I argue that equipoise presses study designers to conduct trials at the point of maximum community uncertainty. Accordingly, equipoise encourages maximum information gain per patient enrolled (or inversel, minimal patient burden per gain in information). As such, equipoise is as much a condition for the ethical conduct of new study designs as it is for old ones. I close by suggesting that, whereas Heymemann et al. suggest new trial designs present a challenge to the operationalization of equipoise, I argue that equipoise presents a challenge for those wishing to operationalize new trial designs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Equity, Ethics and Policy, School of Population and Global Health, McGill University, Montreal, QC, Canada.
ORCID-Profile: Jonathan Kimmelman
Zitieren
APA
Kimmelman, J. (2026). New oncology trial designs and equipoise: Commentary on Heynemann et al. Clinical Trials. https://doi.org/10.1177/17407745261471455
Vancouver
Kimmelman J. New oncology trial designs and equipoise: Commentary on Heynemann et al. Clinical Trials. 2026. doi:10.1177/17407745261471455
BibTeX
@article{Kimmelman2026,
author = {Kimmelman, Jonathan},
title = {New oncology trial designs and equipoise: Commentary on Heynemann et al},
journal = {Clinical Trials},
year = {2026},
doi = {10.1177/17407745261471455}
}
EUVIMED